We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Honokiol decreases alpha-synuclein mRNA levels and reveals novel targets for modulating alpha-synuclein expression.
- Authors
Fagen, Sara J.; Burgess, Jeremy D.; Lim, Melina J.; Amerna, Danilyn; Kaya, Zeynep B.; Faroqi, Ayman H.; Perisetla, Priyanka; DeMeo, Natasha N.; Stojkovska, Iva; Quiriconi, Drew J.; Mazzull, Joseph R.; Delenclos, Marion; Boschen, Suelen L.; McLean, Pamela J.
- Abstract
Background: Intracytoplasmic inclusions comprised of aggregated alpha-synuclein (asyn) represent a key histopathological feature of neurological disorders collectively termed "synucleinopathies," which includes Parkinson's disease (PD). Mutations and multiplications in the SNCA gene encoding asyn cause familial forms of PD and a large body of evidence indicate a correlation between asyn accumulation and disease. Decreasing asyn expression is recognized as a valid target for PD therapeutics, with down-regulation of SNCA expression potentially attenuating downstream cascades of pathologic events. Here, we evaluated if Honokiol (HKL), a polyphenolic compound derived from magnolia tree bark with demonstrated neuroprotective properties, can modulate asyn levels in multiple experimental models. Methods: Human neuroglioma cells stably overexpressing asyn, mouse primary neurons, and human iPSC-derived neurons were exposed to HKLand asyn protein and SNCA messenger RNA levels were assessed. The effect of HKL on rotenone-induced overexpression of asyn levels was further assessed and transcriptional profiling of mouse cortical neurons treated with HKL was performed to identify potential targets of HKL. Results: We demonstrate that HKL can successfully reduce asyn protein levels and SNCA expression in multiple in vitro models of PD with our data supporting a mechanism whereby HKL acts by post-transcriptional modulation of SNCA rather than modulating asyn protein degradation. Transcriptional profiling of mouse cortical neurons treated with HKL identifies several differentially expressed genes (DEG) as potential targets to modulate SNCA expression. Conclusion: This study supports a HKL-mediated downregulation of SNCA as a viable strategy to modify disease progression in PD and other synucleinopathies. HKL has potential as a powerful tool for investigating SNCA gene modulation and its downstream effects.
- Subjects
DRUG therapy for Parkinson's disease; BIOLOGICAL models; IN vitro studies; DISEASE progression; POLYPHENOLS; NERVE tissue proteins; CELL culture; NEURONS; ANALYSIS of variance; SEQUENCE analysis; ANIMAL experimentation; WESTERN immunoblotting; IMMUNOHISTOCHEMISTRY; TREATMENT effectiveness; CELL survival; COMPARATIVE studies; T-test (Statistics); BARK; NEUROPROTECTIVE agents; MESSENGER RNA; SYNUCLEINS; CELL proliferation; GENE expression profiling; DESCRIPTIVE statistics; RESEARCH funding; PLANT extracts; POLYMERASE chain reaction; DATA analysis software; MICE; NEURODEGENERATION; PHARMACODYNAMICS
- Publication
Frontiers in Aging Neuroscience, 2023, p01
- ISSN
1663-4365
- Publication type
Article
- DOI
10.3389/fnagi.2023.1179086